drugset / Trial / NCT00549744

Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing

NCT00549744

Phase 2 Completed 78 enrolled GlaxoSmithKline
RandomizedCrossoverTreatment

Summary

Subjects will attend the unit for out-patient visits on Day 1, Day 7, Day 14 and Day 15 of each treatment period. The washout period between each treatment period will be a minimum of 10 days and maximum of 28 days. Subjects will participate in 3 treatment periods.

Timeline

Start
2007-11-16
Primary completion
2008-08-27
Completion
2008-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK256066 Small molecule Inhaled

Indications